Vanguard Group
CPXX

Vanguard Group’s CELATOR PHARMACEUTICALS INC. COMMON STOCK CPXX Stock Holding History

Vanguard Group’s Portfolio CPXX Stock Details CPXX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-1,256,026
Closed -$37.9M – 4155
2016
Q2 		$37.9M Buy
1,256,026
+447,203
+55% +$9.07M ﹤0.01% 2022
2016
Q1 		$8.92M Buy
808,823
+272,236
+51% +$892K ﹤0.01% 2671
2015
Q4 		$945K Buy
536,587
+23,353
+5% +$40K ﹤0.01% 3647
2015
Q3 		$852K Buy
513,234
+151,643
+42% +$337K ﹤0.01% 3686
2015
Q2 		$810K Buy
361,591
+20,409
+6% +$46.3K ﹤0.01% 3728
2015
Q1 		$843K Buy
341,182
+95,639
+39% +$257K ﹤0.01% 3681
2014
Q4 		$481K Buy
245,543
+21,176
+9% +$43.9K ﹤0.01% 3741
2014
Q3 		$568K Hold
224,367
– – ﹤0.01% 3681
2014
Q2 		$664K Buy
224,367
+34,400
+18% +$94.7K ﹤0.01% 3603
2014
Q1 		$614K Buy
+189,967
New +$643K ﹤0.01% 3602

Vanguard Group's CPXX Position: Q3 2016 in Review

Vanguard Group sold out of CELATOR PHARMACEUTICALS INC. COMMON STOCK (CPXX) in Q3 2016, closing a stake of 1,256,026 shares — an estimated $37.9M sold.

Vanguard Group first reported a position in CPXX in Q1 2014 and held it in 10 quarters. The position peaked at $37.9M in Q2 2016. 0 funds tracked by Wall St. Rank hold CPXX as of Q3 2016.

  • Vanguard Group reported no remaining CELATOR PHARMACEUTICALS INC. COMMON STOCK position as of Q3 2016 after selling out during the quarter.
  • Vanguard Group sold 1,256,026 CELATOR PHARMACEUTICALS INC. COMMON STOCK shares in Q3 2016, an estimated $37.9M.
  • Vanguard Group first reported a position in CELATOR PHARMACEUTICALS INC. COMMON STOCK in Q1 2014 and held it in 10 quarters.
  • Vanguard Group's CELATOR PHARMACEUTICALS INC. COMMON STOCK position peaked at $37.9M in Q2 2016.
  • 0 funds tracked by Wall St. Rank held CELATOR PHARMACEUTICALS INC. COMMON STOCK as of Q3 2016.

Based on Vanguard Group's 13F filing for Q3 2016, filed 14 Nov 2016.